Description: Zelira Therapeutics Limited, a biopharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of a variety of medical conditions in Australia and the United States. It offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops Zenivol, a cannabinoid drug for the treatment of chronic insomnia. The company also provides over the counter products, including SprinJene, an oral care product; and acne treatment products under the RAF FIVE name, as well as Zyraydi, an enhanced distillate capture and dissolution matrix technology. In addition, it offers products for autism and chronic noncancer pain. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited was incorporated in 2003 and is headquartered in Perth, Australia.
Home Page: zeliratx.com
101 St Georges Terrace
Perth,
WA
6000
Australia
Phone:
61 8 6558 0886
Officers
| Name | Title |
|---|---|
| Mr. Osagie O. Imasogie Esq. | Founder & Chairman |
| Dr. Oludare Odumosu | MD, Global CEO & Director |
| Mr. Greg Blake | Executive Director |
| Mr. Timothy Ryan Slate | Company Secretary & Non-Executive Director |
| Mr. Rahul Ganesan | Vice President of Finance & Accounting |
| Dr. Patty Washer | Clinical Trial Consultant |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.3235 |
| Price-to-Sales TTM: | 44.5949 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |